NCT04349306View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Lymphoma
Interventions
DRUG

RASBURICASE SR29142

Pharmaceutical form:solution for infusion Route of administration: intravenous

Trial Locations (1)

Unknown

investigational site CHINA, China

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT04349306 - Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia | Biotech Hunter | Biotech Hunter